LITE STRATEGY INC

LITSNASDAQ

🏆 #3574 by market capEarnings Sep 28US Equity

$0.90▲ $0.03 (+3.57%)

🌙 After hours$0.89▼ 1.00%Regular close · extended-hours price shown

1h—

24h▲ 3.6%

7d▼ 6.5%

14d▼ 7.4%

30d▼ 2.8%

1y▼ 81.4%

🏦Market Cap

$31M

Small Cap

📈Revenue Growth (YoY)

-100.0%

Declining

📊Gross Margin

0.0%

Thin

💵FCF Margin

0.0%

Thin

⚖️P/S Ratio

0.0x

Cheap

Otter Score

Fair

Trading Snapshot

Day Range: $0.89 – $0.91
52-Week Range: $0.69 – $5.50
Volume: $5.68B
Avg Volume: $6.25B
Shares Outstanding: 34.0M
Next Earnings: Sep 27, 2026

Fundamentals Snapshot

Annual Revenue: $5M
Last Q Revenue: $1M
P/E Ratio: -0.1
P/S Ratio: 0.0x
EPS (TTM): $-9.13
Dividend Yield: 0.00%

Why Investors Own LITS

✓High-growth profile — revenue up +21.1% YoY with expanding US Equity exposure.
✓Healthy economics — 39% gross margin and 13% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$5M▲ +15.1% YoY

Gross Margin (TTM)

38.6%▲ +3.7% YoY

Operating Income (TTM)

$1M▲ +15.1% YoY

Free Cash Flow (TTM)

$679,708▲ +15.1% YoY

About LITE STRATEGY INC

Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.

🦦